Uyttenhove C - Search Results

1

Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12.

Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Fallarino F, et al. Among authors: uyttenhove c. Int J Cancer. 1999 Jan 18;80(2):324-33. doi: 10.1002/(sici)1097-0215(19990118)80:2<324::aid-ijc25>3.0.co;2-d. Int J Cancer. 1999. PMID: 9935218

2

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.

Maryanski JL, Marchand M, Uyttenhove C, Boon T. Maryanski JL, et al. Among authors: uyttenhove c. Int J Cancer. 1983 Jan 15;31(1):119-23. doi: 10.1002/ijc.2910310119. Int J Cancer. 1983. PMID: 6187698

3

Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.

Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T. Warnier G, et al. Among authors: uyttenhove c. Int J Cancer. 1996 Jul 17;67(2):303-10. doi: 10.1002/(SICI)1097-0215(19960717)67:2<303::AID-IJC24>3.0.CO;2-A. Int J Cancer. 1996. PMID: 8760603

4

The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.

Uyttenhove C, Godfraind C, Lethé B, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ. Uyttenhove C, et al. Int J Cancer. 1997 Jan 27;70(3):349-56. doi: 10.1002/(sici)1097-0215(19970127)70:3<349::aid-ijc17>3.0.co;2-a. Int J Cancer. 1997. PMID: 9033639

5

Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes.

Van Pel A, De Plaen E, Duffour MT, Warnier G, Uyttenhove C, Perricaudet M, Boon T. Van Pel A, et al. Among authors: uyttenhove c. Cancer Immunol Immunother. 2001 Jan;49(11):593-602. doi: 10.1007/s002620000141. Cancer Immunol Immunother. 2001. PMID: 11225990

6

CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization.

Mazouz N, Ooms A, Moulin V, Van Meirvenne S, Uyttenhove C, Degiovanni G. Mazouz N, et al. Among authors: uyttenhove c. Cancer Immun. 2002 Mar 27;2:2. Cancer Immun. 2002. PMID: 12747747

7

The p815 mastocytoma tumor model.

Gajewski TF, Markiewicz MA, Uyttenhove C. Gajewski TF, et al. Among authors: uyttenhove c. Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.4. doi: 10.1002/0471142735.im2004s43. Curr Protoc Immunol. 2001. PMID: 18432777

8

Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer.

Field S, Uyttenhove C, Stroobant V, Cheou P, Donckers D, Coutelier JP, Simpson PT, Cummings MC, Saunus JM, Reid LE, Kutasovic JR, McNicol AM, Kim BR, Kim JH, Lakhani SR, Neville AM, Van Snick J, Jat PS. Field S, et al. Among authors: uyttenhove c. Int J Cancer. 2016 Apr 15;138(8):1959-70. doi: 10.1002/ijc.29946. Epub 2015 Dec 21. Int J Cancer. 2016. PMID: 26619948 Free article.

9

Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity.

Puccetti P, Bianchi R, Fioretti MC, Ayroldi E, Uyttenhove C, Van Pel A, Boon T, Grohmann U. Puccetti P, et al. Among authors: uyttenhove c. Eur J Immunol. 1994 Jun;24(6):1446-52. doi: 10.1002/eji.1830240631. Eur J Immunol. 1994. PMID: 8206103

10

Interleukin-9.

Renauld JC, Houssiau F, Druez C, Uyttenhove C, Vink A, Van Snick J. Renauld JC, et al. Among authors: uyttenhove c. Int Rev Exp Pathol. 1993;34 Pt A:99-109. Int Rev Exp Pathol. 1993. PMID: 8454421 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results